Genetic structure,clonality and diversity in commercial pomegranate (Punica granatum L.) cultivars

Genetic Resources and Crop Evolution - The pomegranate fruit is one of the most important horticultural products due to the presence of polyphenols, anti-oxidant and anti-fungal compounds. In the...     

The central role of lipoproteins in the pathogenesis of mycoplasmoses

Mycoplasmas are a diverse group of pathogens responsible for disease in a wide range of animal species. In recent years there have been considerable advances in knowledge of the proteins and structures involved in adherence in some mycoplasmas, but understanding of the biochemical functions and roles in virulence of another central feature of mycoplasmas, their lipoproteins, continues to develop. The aim of this review is to examine current knowledge of the roles of lipoproteins in the pathogenicity and the evolution of virulence in those mycoplasmas causing disease in domestic animals. Those lipoproteins that have been characterised have roles in adherence, in transport of nutrients into the mycoplasma cell, and in enzymatic interactions with the host. Furthermore they appear to play a prominent role in both inducing the host immune response to infection and in facilitating evasion of this response, particularly through the generation of dramatic levels of antigenic variation on the cell surface. Recent genomic comparisons of several pathogenic mycoplasmas have identified a further level of interaction between lipoproteins and pathogenicity. In several pathogens large scale horizontal gene transfer between distantly related mycoplasma species has resulted in the acquisition of a large number of genes, including those encoding lipoproteins thought to play a role in virulence, by one mycoplasma from another inhabiting the same host species. The interactions between these horizontally transferred genes, their new mycoplasma host and the animal that it infects may be an important contributing factor in the pathogenesis of some mycoplasmoses.     

Onset of immunity with Mycoplasma synoviae: comparison of the live attenuated vaccine MS-H (Vaxsafe MS) with its wild-type parent strain (86079/7NS)

The onset of protective immunity with MS-H was determined through experimental challenge and compared with the parent strain 86079/7NS. MS-H vaccinates and 86079/7NS inoculates were challenged at 1, 2, 3, 4, 5, and 6 wk after vaccination, then examined 2 wk after challenge for signs of respiratory disease. Serologic results indicated that 100% of MS-H vaccinates had antibodies to MS by 3 wk after vaccination and 100% of 86079/7NS inoculates were positive by 2 wk after inoculation. From 3 wk after vaccination, MS-H vaccinates had a significantly lower incidence of air sac lesions and, from 4 wk after vaccination, a significantly lower air sac lesion severity. In 86079/7NS-inoculated birds, a significantly lower incidence of air sac lesions was observed from 1 wk after inoculation, and air sac lesion severity was significantly lower than the unvaccinated controls at 3 wk after inoculation. It would appear that, under the conditions of this experiment, protective immunity elicited by MS-H appeared at 4 wk after vaccination, slightly later than the appearance of serum antibody. Although the MS-H vaccine was slower to establish protective immunity than 86079/7NS, there was no significant difference between the two strains by 4 wk after vaccination or inoculation.     

Uptake of Heavy Metals by Mycorrhizal Barley (Hordeum vulgare L.)

It has been previously indicated that arbuscular mycorrhizal (AM) fungi can enhance the bioremediation abilities of their host plant. Barley (Hordeum vulgare L.) is a crop plant with some unique physiological properties, such as tolerance to salinity. However, its tolerance to other stresses such as heavy metals must be tested. Accordingly, it was hypothesized that barley can be efficiently used to treat heavy metals in symbiotic and non-symbiotic association with AM fungi. In a greenhouse experiment barley plants were inoculated with the AM species Glomus mosseae and grown in a soil polluted with cadmium (Cd), cobalt (Co), and lead (Pb). Relative to Cd and Co, mycorrhizal barley absorbed significantly higher amounts of Pb. AM species also significantly decreased Cd and Co uptake by barley indicating the alleviating effects of G. mosseae on the stress of such heavy metals.     

Epidemiology of recent outbreaks of infectious laryngotracheitis in poultry in Australia

Objective Over the past 3 years, numerous outbreaks of infectious laryngotracheitis (ILT) have occurred in poultry in Australia. The objectives of this study were to identify the viral strains involved in the recent outbreaks and to determine possible epidemiological links between these outbreaks. Procedure A combination of polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses of several genes of the ILT virus was used to identify genetic differences in field/vaccine ILT virus isolates. In a previous study, these procedures had demonstrated five classes (1–5) in Australia. Results Analysis of 92 field ILT viruses demonstrated four new classes: 6, 7, 8 and 9. Class 6 was responsible for four outbreaks in one Victorian broiler company and demonstrated to be distinct from other Australian strains of ILT. Class 7 was the Nobilis ILT vaccine (Intervet Pty Ltd). Class 8 was responsible for the majority of the outbreaks in New South Wales and was phylogenetically close to class 7. On one occasion, classes 7 and 8 were identified in an outbreak on a Victorian farm that had used the Nobilis ILT vaccine. Class 9, also phylogenetically close to classes 7 and 8, was found only in New South Wales. The previously identified class 2 was also found to be responsible for a large number of outbreaks, mainly in Victoria. Conclusion The results demonstrate that, epidemiologically, most outbreaks of ILT in New South Wales are unrelated to those in Victoria and suggest a link between classes 8 and 9 and the Nobilis ILT vaccine (class 7).     

Detection of antibodies to Mycoplasma gallisepticum vaccine ts-11 by an autologous pMGA enzyme-linked immunosorbent assay

Mycoplasma gallisepticum is a poultry pathogen that causes respiratory disease and loss of egg production worldwide. A live attenuated vaccine, ts-11, has been used for control of M. gallisepticum in several countries. The rapid serum agglutination test is usually used as an indicator of flock response to vaccination; however, in some flocks, the detected response may be weak or absent. With the use of specific monoclonal antibodies against M. gallisepticum strain S6 pMGA in immunoaffinity purification, the major membrane antigen of ts-11 was purified. An indirect enzyme-linked immunosorbent assay (ELISA) was developed with the purified antigen, and its potential for detection of antibodies induced after ts-11 vaccination was compared with an indirect ELISA with M. gallisepticum strain S6 pMGA. In the presence of high levels of ts-11-induced antibodies, both antigens detected similar numbers of positive sera. However, when lower levels of antibodies were present, ts-11 pMGA showed a higher sensitivity than S6 pMGA. Further examination of ts-11 pMGA with Mycoplasma synoviae-infected chicken sera revealed that ts-11 pMGA is specific for M. gallisepticum antibodies. With a panel of sera from ts-11-vaccinated or non-ts-11-vaccinated field chickens, the ts-11 pMGA ELISA was found to be more sensitive than the commercial rapid serum agglutination test in detecting antibodies to ts-11 vaccine. The results from this study suggest that the major membrane antigen of M. gallisepticum may have slightly different antigenic profiles in different strains, thereby necessitating the use of autologous antigens in serodiagnostic assays to increase sensitivity of the tests for mycoplasma antibodies. Thus, the low level of antibody response after ts-11 vaccination is, at least partially, due to the low ability of the current diagnostic antigens to bind ts-11 antibodies.     

Determination of the effective dose of the live Mycoplasma synoviae vaccine, Vaxsafe MS (strain MS-H) by protection against experimental challenge

The minimum effective dose of the Mycoplasma synoviae-H (MS-H) vaccine was determined through protection against experimental challenge. Chickens were vaccinated by eyedrop with the following doses of a vaccine: 1.2 x 10(5), 2.4 x 10(5) 4.8 x 10(5), 9.6 x 10(5), 1.92 X 10(6), and 3.84 X 10(6) color change units (CCU), then challenged 6 wk after vaccination. Rapid serum agglutination results indicated that 100% of birds receiving an MS-H dose of > or = 4.8 x 10(5) CCU had antibodies to MS and enzyme-linked immunosorbent assay results showed that 60% of birds receiving a dose of 4.8 x 10(5) or 9.6 x 10(5) CCU and 100% of birds receiving a dose of 1.92 x 10(6) or 3.84 x 10(6) had antibodies to MS. At postmortem after challenge, the following parameters were significantly lower in birds vaccinated with an MS-H dose of > or = 4.8 x 10(5) CCU: air sac (AS) lesion severity; incidence of AS lesions; mucosal thicknesses in the upper trachea, middle trachea, and lower trachea (LT); and MS colonization of the LT and AS. It was concluded that an MS-H dose of 4.8 x 10(5) CCU was sufficient to elicit an antibody response in birds, prevent MS colonization in the LT and AS, and protect against AS lesions caused by an experimental MS and infectious bronchitis virus challenge.     

Attenuated vaccines can recombine to form virulent field viruses

Recombination between herpesviruses has been seen in vitro and in vivo under experimental conditions. This has raised safety concerns about using attenuated herpesvirus vaccines in human and veterinary medicine and adds to other known concerns associated with their use, including reversion to virulence and disease arising from recurrent reactivation of lifelong chronic infection. We used high-throughput sequencing to investigate relationships between emergent field strains and vaccine strains of infectious laryngotracheitis virus (ILTV, gallid herpesvirus 1). We show that independent recombination events between distinct attenuated vaccine strains resulted in virulent recombinant viruses that became the dominant strains responsible for widespread disease in Australian commercial poultry flocks. These findings highlight the risks of using multiple different attenuated herpesvirus vaccines, or vectors, in the same populations.